The transcription factor Sox11 is a prognostic factor for improved recurrence-free survival in epithelial ovarian cancer

Donal Brennan, Sara Ek, Emma Doyle, Thomas Drew, Michael Foley, Grainne Flannelly, Darren P O´Conner, William M Gallagher, Sami Kilpinen, Olli-Pekka Kallioniemi, Karin Jirström, Colm O'Herlihy, Carl Borrebaeck

Research output: Contribution to journalArticlepeer-review

Abstract

Abstract
Background:
Current prognostic molecular markers for epithelial ovarian cancer (EOC) are
insufficient. The aim of the current study was to investigate the role of Sox11 in EOC
Methods:
Using an in silico transcriptomic screen Sox11 was identified as a potential EOC
biomarker. Sox11 protein expression was evaluated using immunohistochemistry (IHC)
in 76 EOC cases, which were analyzed using automated algorithms to develop a
quantitative scoring model.
Results:
Sox11 mRNA expression was up-regulated in EOC compared to normal tissues.
Automated analysis of Sox11 in the EOC cohort revealed high expression of Sox11, in
40% of tumours, who had an improved recurrence free survival (RFS) (p= 0.002).
Multivariate analysis confirmed Sox11 was an independent predictor of improved RFS
after controlling for stage and grade.
Conclusions:
These data suggest that Sox11 is a new prognostic marker in EOC. Loss of SOX 11 is
associated with a decreased RFS and a more aggressive phenotype.
Original languageEnglish
Pages (from-to)1510-1517
JournalEuropean Journal of Cancer
Volume45
Issue number8
DOIs
Publication statusPublished - 2009

Subject classification (UKÄ)

  • Immunology in the medical area

Fingerprint

Dive into the research topics of 'The transcription factor Sox11 is a prognostic factor for improved recurrence-free survival in epithelial ovarian cancer'. Together they form a unique fingerprint.

Cite this